A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
Patients with cancer, particularly those with metastatic cancer, are at high risk of venous thromboembolism (VTE), which places a huge burden on healthcare resources and can adversely affect patients' prognosis. In addition, VTE can have a negative impact on quality of life and increase the management challenges faced by physicians and nurses. Conventional long-term treatment using vitamin K antagonists, such as warfarin, presents many practical problems for cancer patients including frequent monitoring and dose adjustment, drug interactions, and disruption of anticoagulation for invasive procedures. The aim of this article is to review the potential advantages of using low molecular weight heparin (LMWH) in the treatment of cancer-related VTE in comparison to conventional therapy with warfarin or standard heparin. The potential advantages were determined via a literature review. LMWH is at least as effective as standard heparin or warfarin, and has been shown to have several benefits over warfarin in cancer patients. The simplicity of this therapy enables patients to be treated at home, and has been shown to have a positive impact on overall quality of life. The use of LMWH provides a treatment alternative to patients with cancer offering them hope and optimism regarding their care.
University College London, Chenies Mews, UK. s.rhodes@ucl.ac.uk
Sue
S
Rhodes
Sarah
S
Bond
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001294:Attitude to Health; D004334:Drug Administration Schedule; D004347:Drug Interactions; D016903:Drug Monitoring; D055317:Evidence-Based Practice; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D009859:Oncology Nursing; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011788:Quality of Life / Q000523:psychology; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology* / Q000523:psychology; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin